HOME >> MEDICINE >> NEWS
Novel drugs help solve Gleevec resistance

SAN DIEGO - Two different novel targeted therapies can produce strong responses in patients who have become resistant to Gleevec(tm), the standard therapy for chronic myeloid leukemia (CML), researchers at The University of Texas M. D. Anderson Cancer Center are reporting.

Researchers say the benefits offered by these drugs, BMS-354825 and AMN107, appear to be promising for treatment of relapsed CML and offer an immediate effective option for the minority of patients who do not achieve an optimal response to Gleevec therapy.

M. D. Anderson Cancer Center, the only institution to have tested both of these novel compounds, undertook independent Phase I clinical trials of both agents. It conducted the study of BMS-354825 in conjunction with the University of California, Los Angeles, and the study of AMN107 with the University of Frankfurt, in Germany. The M. D. Anderson researchers will discuss their experiences using these agents in patients with leukemia at the American Society of Hematology (ASH) meeting.

BMS-354825 "shows remarkable activity"

In the study conducted at M. D. Anderson and at UCLA School of Medicine, the majority of patients with advanced, Gleevec-resistant CML have responded to the drug BMS-354825, says Moshe Talpaz, M.D., a professor in the Department of Experimental Therapeutics at M. D. Anderson.

Of 11 patients with advanced "blast phase" CML, seven have had a hematologic response from the drug (defined as control of white blood cell counts). Of these, three patients experienced a complete hematologic response (disappearance of all findings consistent with advanced stage CML, and return of blood counts to normal), while two patients showed no evidence of leukemia. Two other patients had their CML downgraded to "chronic." Additionally, of the 11 patients, four have had a major "cytogenetic response" (defined as elimination of cells with the cancer-causing defect), and two had minor cytogenetic response
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-794-1584
University of Texas M. D. Anderson Cancer Center
5-Dec-2004


Page: 1 2 3 4 5

Related medicine news :

1. Novel therapy tested in mice could chase away cat allergies
2. Novel antibiotic shows promise in shortening treatment duration of tuberculosis
3. Novel p53 gene-based therapy boosts immune system and reduces tumor size
4. Novel imaging technique shows abnormal brain anatomy in children with ADHD
5. Novel drug-antidote strategy provides greater control of drug action
6. Novel imaging technique shows lymph nodes, metastases in breast cancer without surgery
7. Novel delivery method for nutrients wins Kaye Innovation Award for Hebrew university students
8. Novel vitamin discovery offers clues for cancer chemotherapy and lipid disorders
9. Novel findings about neovessel formation
10. Novel MRI technique provides clear images of blood flow
11. Novelty-seeking teens may be more easily influenced by tobacco advertisements

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2019)... , ... June 13, 2019 , ... Clinical Ink ... is pleased to announce that Jonathan Andrus , chief business officer at Clinical ... the Duke-Margolis Center for Health Policy on July 1, 2019, in Washington, ...
(Date:6/13/2019)... ... 13, 2019 , ... The University of Pittsburgh School of Health and Rehabilitation ... (MSHI ) degree program to address the growing need for professionals who can use ... a larger effort for SHRS to bring more graduate degrees online. The Master of ...
(Date:6/13/2019)... NEW YORK (PRWEB) , ... June 13, 2019 ... ... Values in Patients Taking SGLT-2 Inhibitors” presented at the American Diabetes Association (ADA) ... 2 diabetes that are being treated with an SGLT-2 inhibitor. SGLT-2 inhibitors are ...
(Date:6/12/2019)... Va. (PRWEB) , ... June 12, 2019 , ... ... Andrea Miller, a quality assurance expert with more than 25 years of experience ... MDD Compliance for all classes of medical devices, has joined NDA Partners as ...
(Date:6/12/2019)... YORK (PRWEB) , ... June 12, 2019 , ... ... travel management companies headquartered in the U.S., today announced that its Chairman and ... highest annual honor. The award was presented last Wednesday evening at New York ...
Breaking Medicine News(10 mins):
(Date:6/6/2019)... ... 2019 , ... MEDICC (Medical Education Cooperation with Cuba) has deplored the Trump ... is one more assault on the freedom of Americans, Cuban-Americans and the health and ... Board of Directors. , MEDICC has long stood for open dialogue and cooperation ...
(Date:6/6/2019)... HUNTINGTON, W.Va. (PRWEB) , ... June 05, 2019 ... ... social service providers helping families affected by substance use disorder, held an open ... CARES) in Huntington. , The open house was coordinated by Quality Insights, ...
(Date:6/6/2019)... ... , ... The number of neonatal therapists is on the ... of Certified Neonatal Therapist (CNT). It highlights specialized professionals who have achieved standards ... National Certification Board (NTNCB). Today, more than 300 professionals internationally are CNTs; they ...
Breaking Medicine Technology:
Cached News: